EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy

Simon J Hume iD, Danny K Wong, Man-Fung Yuen iD, Kathy Jackson, Sara Bonanzinga, Sara Vogrin, Samuel A L Hall, Gareth S Burns, Paul V Desmond, Vijaya Sundararajan, Dilip Ratnam, Miriam T Levy und 14 weitere

Liver International · 2024

DOI: 10.1111/liv.16029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Simon J Hume und 25 weiteren Autor:innen. Beteiligte Einrichtung: St Vincent's Hospital Melbourne, Fitrozy, Victoria, Australia. Hauptthemen laut MEDLINE: Hepatitis B Core Antigens, Antiviral Agents, Hepatitis B, Chronic, Biomarkers. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core‐related antigen (HBcrAg) level as a biomarker for predicting outcomes after NA discontinuation.

Methods

Patients with HBeAg‐negative chronic hepatitis B (CHB) without cirrhosis were enrolled in a prospective trial evaluating clinical outcomes until 96 weeks after NA discontinuation. End of treatment (EOT) and off‐treatment levels of serum HBcrAg, HBsAg, HBV RNA and HBV DNA were used to predict key clinical outcomes including hepatitis flare (ALT ≥5 × ULN and HBV DNA > 2000 IU/mL). The SCALE‐B score was calculated for the purposes of model validation.

Results

HBcrAg was tested amongst 65 participants. The median age was 54 years, 54% were male and 83% were Asian. HBcrAg was detectable in 86% patients. HBcrAg level ≥4 log U/mL at EOT was predictive of hepatitis flare [8/10 (80%) vs. 17/55 (31%), p = .001]. The presence of either HBcrAg ≥4 log U/mL or detectable HBV RNA at EOT predicted for both biochemical relapse and hepatitis flare. The SCALE‐B model at EOT predicted for virological relapse, biochemical relapse, hepatitis flare and HBsAg loss in this cohort. An increase in the serum HBcrAg level off‐treatment was also associated with hepatitis flare. No participant with EOT HBcrAg level ≥4 log U/mL achieved HBsAg loss.

Conclusions

High levels of serum HBcrAg predict for hepatitis flare after stopping NA therapy and low likelihood of HBsAg loss at week 96. People with high levels of serum HBcrAg are not suitable candidates for NA discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Core AntigensAntiviral AgentsHepatitis B, ChronicBiomarkersDNA, ViralHepatitis B virusHumansMaleFemaleMiddle AgedProspective StudiesAdultHepatitis B Surface AntigensRNA, ViralWithholding TreatmentSymptom Flare UpAged

Stichwörter der Autor:innen

biomarkerhepatitis Bhepatitis B core‐related antigenhepatitis flarenucleot(s)ide analoguenucleot(s)ide analogue discontinuation

Substanzen

Hepatitis B Core AntigensAntiviral AgentsBiomarkersDNA, ViralHepatitis B Surface AntigensRNA, Viral

Autor:innen und Institutionen

  • St Vincent's Hospital Melbourne, Fitrozy, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
  • Victorian Infectious Diseases Reference Laboratory, Department of Infectious Diseases, Royal Melbourne Hospital, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Au…
  • Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Western Health, Melbourne, Australia.
  • Monash Health, Melbourne, Victoria, Australia.

ORCID-Profile: Simon J Hume, Man-Fung Yuen, Simone I Strasser, Marie Sinclair

Zitieren

APA

Hume, S. J., Wong, D. K., Yuen, M. F., Jackson, K., Bonanzinga, S., Vogrin, S., Hall, S. A. L., Burns, G. S., Desmond, P. V., Sundararajan, V., Ratnam, D., Levy, M. T., Lubel, J. S., Nicoll, A. J., Strasser, S. I., Sievert, W., Ngu, M. C., Sinclair, M., Meredith, C., …, & Thompson, A. J. (2024). High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy. Liver International. https://doi.org/10.1111/liv.16029

Vancouver

Hume SJ, Wong DK, Yuen MF, Jackson K, Bonanzinga S, Vogrin S, et al. High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy. Liver International. 2024. doi:10.1111/liv.16029

BibTeX
@article{Hume2024,
  author = {Hume, Simon J and Wong, Danny K and Yuen, Man-Fung and Jackson, Kathy and Bonanzinga, Sara and Vogrin, Sara and Hall, Samuel A L and Burns, Gareth S and Desmond, Paul V and Sundararajan, Vijaya and Ratnam, Dilip and Levy, Miriam T and Lubel, John S and Nicoll, Amanda J and Strasser, Simone I and Sievert, William and Ngu, Meng C and Sinclair, Marie and Meredith, Christopher and Matthews, Gail and Revill, Peter A and Littlejohn, Margaret and Bowden, Scott and Visvanathan, Kumar and Holmes, Jacinta A and Thompson, Alexander J},
  title = {High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16029}
}
Kostenlos starten →